Home About Us Government Relations and Advocacy Media Contact Us Site Map Privacy Français  
Multiple Sclerosis Society of CanadaSociété canadienne de la sclérose en plaquesfinding a cure - enhancing quality of life
Multiple Sclerosis Living with Multiple Sclerosis Treatments Donate Now Get Involved Special Events


    share +

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

View or print this bulletin in its original format.

You will need ADOBE ACROBAT READER to view this document listed above - it's FREE.

Medical Update Memo
July 22, 2010


FTY720 (Fingolimod) is a new therapy that reduces disease activity by decreasing numbers of a specific immune system cell. The authors investigated patients who discontinued therapy during clinical investigation and they found that the reconstitution of this specific cell-type after prolonged FTY720 therapy can be significantly greater than predicted. Johnson TA, Shames I, Keezer M, Lapierre Y, Haegert DG, Bar-Or A, Antel J. Clin Immunol. 2010 Jul 2.


FTY720 (Fingolimod) reduces multiple sclerosis disease activity by inducing lymphopenia and inhibiting lymphocyte re-entry from lymph nodes. Peripheral lymphocyte reconstitution following drug discontinuation has been considered relatively rapid (2-4weeks), based on short-term studies. Authors investigated the kinetics of lymphocyte reconstitution in MS patients in open label extension phases of FTY720 clinical trials who discontinued therapy after prolonged use (>1-5years), and examined histological features of a mediastinal lymph node obtained from a lymphopenic FTY720 patient.

Although three patients showed reconstitution of peripheral lymphocytes within the predicted timeline, two patients continued to be lymphopenic 9 and 34months after therapy cessation. Lymph nodes from the latter patient showed preserved architecture. Notwithstanding preserved lymph node integrity, time for lymphocyte reconstitution after prolonged FTY720 therapy can be significantly greater than predicted by shorter-term studies. This is relevant for clinical decisions regarding management of patients using this therapy and for introducing alternate therapies.


National Research and Programs
Offert en français.

share +

The Multiple Sclerosis Society of Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy, but provides information to assist individuals in making their own decisions.

Back to top

Charitable registration
10774 6174 RR0001
Multiple Sclerosis Society of Canada
Toll free to reach the nearest regional office: 1 800 268-7582

To locate the MS Society office near you, please select your region:

E-mail: info@mssociety.ca
(Please provide your town and province in your e-mail)

Multiple Sclerosis   Living with MS   Research   Treatments   Donate Now   Get Involved    Special Events

Home    About Us    Advocacy    Media    Contact Us    Site Map    Privacy    Français